Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KURA NASDAQ:PHAT NASDAQ:QTTB NASDAQ:SANA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKURAKura Oncology$9.05+2.1%$9.31$5.45▼$12.49$803.40M0.362.20 million shs1.30 million shsPHATPhathom Pharmaceuticals$10.37+1.0%$11.52$7.61▼$18.31$827.07M0.51.10 million shs554,284 shsQTTBQ32 Bio$12.64-0.5%$7.52$1.35▼$14.85$214.32M0.271.61 million shs326,330 shsSANASana Biotechnology$2.68-3.2%$3.22$2.41▼$6.55$745.82M2.143.70 million shs2.25 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKURAKura Oncology+2.14%+3.55%-4.54%+4.62%+30.78%PHATPhathom Pharmaceuticals+0.97%+2.37%-17.44%0.00%+14.71%QTTBQ32 Bio-0.47%-3.59%+112.79%+85.34%+643.53%SANASana Biotechnology-3.25%0.00%-16.25%-20.24%-0.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKURAKura Oncology$9.05+2.1%$9.31$5.45▼$12.49$803.40M0.362.20 million shs1.30 million shsPHATPhathom Pharmaceuticals$10.37+1.0%$11.52$7.61▼$18.31$827.07M0.51.10 million shs554,284 shsQTTBQ32 Bio$12.64-0.5%$7.52$1.35▼$14.85$214.32M0.271.61 million shs326,330 shsSANASana Biotechnology$2.68-3.2%$3.22$2.41▼$6.55$745.82M2.143.70 million shs2.25 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKURAKura Oncology+2.14%+3.55%-4.54%+4.62%+30.78%PHATPhathom Pharmaceuticals+0.97%+2.37%-17.44%0.00%+14.71%QTTBQ32 Bio-0.47%-3.59%+112.79%+85.34%+643.53%SANASana Biotechnology-3.25%0.00%-16.25%-20.24%-0.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKURAKura Oncology 2.69Moderate Buy$25.58182.69% UpsidePHATPhathom Pharmaceuticals 2.86Moderate Buy$24.50136.26% UpsideQTTBQ32 Bio 2.60Moderate Buy$13.506.80% UpsideSANASana Biotechnology 2.67Moderate Buy$9.50254.48% UpsideCurrent Analyst Ratings BreakdownLatest QTTB, SANA, PHAT, and KURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2026KURAKura Oncology Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight6/4/2026KURAKura Oncology CLSASubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.006/4/2026KURAKura Oncology Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.005/28/2026KURAKura Oncology OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.005/28/2026KURAKura Oncology Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.005/28/2026KURAKura Oncology CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/22/2026QTTBQ32 Bio MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$14.005/22/2026QTTBQ32 Bio MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$14.005/18/2026QTTBQ32 Bio Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight5/18/2026QTTBQ32 Bio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/11/2026QTTBQ32 Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKURAKura Oncology$67.48M11.91N/AN/A$2.00 per share4.53PHATPhathom Pharmaceuticals$175.11M4.72N/AN/A($6.14) per share-1.69QTTBQ32 Bio$53.74M3.99$1.52 per share8.34$3.41 per share3.71SANASana BiotechnologyN/AN/AN/AN/A$0.60 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKURAKura Oncology-$278.67M-$3.35N/AN/AN/A-411.19%-141.95%-43.28%8/6/2026 (Estimated)PHATPhathom Pharmaceuticals-$221.25M-$2.12N/A6.65N/A-76.77%N/A-44.29%8/6/2026 (Estimated)QTTBQ32 Bio$29.82M$2.667.31N/AN/AN/A149.23%34.50%8/5/2026 (Estimated)SANASana Biotechnology-$244.17M-$0.93N/AN/AN/AN/A-108.01%-40.68%8/10/2026 (Estimated)Latest QTTB, SANA, PHAT, and KURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026KURAKura Oncology-$0.88-$0.83+$0.05-$0.83$25.97 million$18.27 million5/11/2026Q1 2026SANASana Biotechnology-$0.15-$0.14+$0.01-$0.17N/AN/A5/5/2026Q1 2026QTTBQ32 Bio-$0.68-$0.54+$0.14-$0.54$39.74 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKURAKura OncologyN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/AQTTBQ32 BioN/AN/AN/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKURAKura Oncology0.096.156.14PHATPhathom PharmaceuticalsN/A2.212.16QTTBQ32 Bio0.045.365.36SANASana BiotechnologyN/A1.291.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKURAKura OncologyN/APHATPhathom Pharmaceuticals99.01%QTTBQ32 Bio31.32%SANASana Biotechnology88.23%Insider OwnershipCompanyInsider OwnershipKURAKura Oncology7.60%PHATPhathom Pharmaceuticals9.33%QTTBQ32 Bio40.00%SANASana Biotechnology25.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKURAKura Oncology13088.77 million82.03 millionOptionablePHATPhathom Pharmaceuticals11079.76 million72.32 millionOptionableQTTBQ32 Bio3916.96 million10.17 millionN/ASANASana Biotechnology380278.29 million207.61 millionOptionableQTTB, SANA, PHAT, and KURA HeadlinesRecent News About These CompaniesHarbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific AdvisorJune 12 at 11:46 PM | finance.yahoo.comAs the GLP-1 race heats up, how can investors position themselves for the next wave of innovation?June 10 at 10:28 PM | msn.comSana Biotechnology, Inc. (SANA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 10 at 3:01 AM | seekingalpha.comSana Biotechnology, Inc. (NASDAQ:SANA) Given Consensus Rating of "Moderate Buy" by AnalystsJune 7, 2026 | americanbankingnews.comSana Biotechnology (NASDAQ:SANA) Downgraded by Wall Street Zen to SellJune 7, 2026 | americanbankingnews.comSana Biotechnology Shareholders Reelect Directors and Ratify AuditorJune 5, 2026 | tipranks.comDid Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?June 2, 2026 | prnewswire.comSana Biotechnology to Present at June 2026 Investor ConferencesMay 27, 2026 | globenewswire.comSana Biotechnology Raises $69 Million Through Equity OfferingMay 15, 2026 | tipranks.comSana Biotechnology Shares Fall on Sale of $69 Million in Shares Through At-The-Market FacilityMay 15, 2026 | marketwatch.comSana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) FacilityMay 15, 2026 | globenewswire.comSana Biotechnology (SANA) Receives a Buy from WedbushMay 14, 2026 | theglobeandmail.comBank of America Securities Keeps Their Buy Rating on Sana Biotechnology (SANA)May 13, 2026 | theglobeandmail.comSana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell ...May 13, 2026 | markets.businessinsider.comSana Biotechnology, Inc. (SANA) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comSana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPsMay 12, 2026 | globenewswire.comSana: Q1 Earnings SnapshotMay 12, 2026 | finance.yahoo.comSana Biotechnology Reports First Quarter 2026 Financial Results and Business UpdatesMay 12, 2026 | markets.businessinsider.comSana Biotechnology to Present at the BofA Securities 2026 Healthcare ConferenceMay 5, 2026 | globenewswire.comSana to present in vivo CAR T data as Janux drops trialApril 28, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQTTB, SANA, PHAT, and KURA Company DescriptionsKura Oncology NASDAQ:KURA$9.05 +0.19 (+2.14%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$9.06 +0.00 (+0.06%) As of 06/12/2026 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.Phathom Pharmaceuticals NASDAQ:PHAT$10.37 +0.10 (+0.97%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$10.38 +0.01 (+0.10%) As of 06/12/2026 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.Q32 Bio NASDAQ:QTTB$12.64 -0.06 (-0.47%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$12.62 -0.02 (-0.12%) As of 06/12/2026 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.Sana Biotechnology NASDAQ:SANA$2.68 -0.09 (-3.25%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$2.70 +0.02 (+0.75%) As of 06/12/2026 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears This Energy Stock Has Quietly Soared 130% in a Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
